Concert Pharmaceuticals Inc. (CNCE)

5.89
NASDAQ : Health Technology
Prev Close 5.88
Day Low/High 5.82 / 6.26
52 Wk Low/High 5.36 / 17.83
Avg Volume 210.30K
Exchange NASDAQ
Shares Outstanding 23.80M
Market Cap 139.94M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
10 Best Nasdaq Biotech Stocks in the Third Quarter

10 Best Nasdaq Biotech Stocks in the Third Quarter

Here are the 10 stocks in the biotech sector which had the best third-quarter.

New Lifetime High Reached By Concert Pharmaceuticals (CNCE)

New Lifetime High Reached By Concert Pharmaceuticals (CNCE)

Trade-Ideas LLC identified Concert Pharmaceuticals (CNCE) as a new lifetime high candidate

Concert Pharmaceuticals Announces Results Of A Phase 1 Trial That Demonstrates CTP-656 Achieved A Superior Pharmacokinetic Profile To Kalydeco®

Concert Pharmaceuticals Announces Results Of A Phase 1 Trial That Demonstrates CTP-656 Achieved A Superior Pharmacokinetic Profile To Kalydeco®

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced positive data from a Phase 1 single ascending dose clinical trial of CTP-656.

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Wells Fargo Securities 2015 Healthcare...

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Company Update

Concert Pharmaceuticals Reports Second Quarter 2015 Financial Results And Provides Company Update

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2015.

Concert Pharmaceuticals To Report Second Quarter 2015 Financial Results On August 5, 2015

Concert Pharmaceuticals To Report Second Quarter 2015 Financial Results On August 5, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2015 financial results on Wednesday, August 5, 2015, before the U.

Insider Trading Alert - CNCE, UVE And EBSB Traded By Insiders

Insider Trading Alert - CNCE, UVE And EBSB Traded By Insiders

Stocks with insider trader activity include CNCE, UVE and EBSB

Concert Pharmaceuticals Receives $50 Million Payment From Auspex Pharmaceuticals

Concert Pharmaceuticals Receives $50 Million Payment From Auspex Pharmaceuticals

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a payment of $50.

Concert Pharmaceuticals To Present At Two Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Two Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Jefferies 2015 Global Healthcare Conference...

Concert Pharmaceuticals To Present At The UBS Global Healthcare Conference

Concert Pharmaceuticals To Present At The UBS Global Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the UBS Global Healthcare Conference on Tuesday, May 19, 2015 at 11:30 a.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AEY, ALSK, CNCE, CYRN, IBM, KFS, LUK, MGNX, MOCO, TSC, TTI Downgrades: ABT, BIOS, FARM, HGR, ING, IRT, MAG, PHG, PRO Initiations: AMBR, CORI, STKS Read on to get TheStreet Quant Ratings' detailed report:

Flamel Jumps After Competitors Scrap Narcolepsy Drug Development

Flamel Jumps After Competitors Scrap Narcolepsy Drug Development

The shares of Flamel Technologies are rallying after two other companies, Jazz Pharmaceuticals and Concert Pharmaceuticals, decided not to continue development of their JZP-386 drug at this time.

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

Concert Pharmaceuticals Reports First Quarter 2015 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2015.

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals To Report First Quarter 2015 Financial Results On May 8, 2015

Concert Pharmaceuticals To Report First Quarter 2015 Financial Results On May 8, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2015 financial results on Friday, May 8, 2015 before the U.

Concert Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference

Concert Pharmaceuticals To Present At 14th Annual Needham Healthcare Conference

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the 14 th Annual Needham Healthcare Conference, Tuesday, April 14, 2015 at 4:20 p.

Concert Pharmaceuticals Announces Pricing Of Public Offering

Concert Pharmaceuticals Announces Pricing Of Public Offering

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the pricing of an underwritten public offering of 3,300,000 shares of its common stock at a public offering price of $15.

Concert Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Concert Pharmaceuticals Announces Proposed Public Offering Of Common Stock

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has commenced an underwritten public offering of its common stock.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXE, FF, HTBI Downgrades: ANN, CLGX, FTD, GSVC, NGS, QSII, RNET, TSU Initiations: AMDA, CNCE, IBP Read on to get TheStreet Quant Ratings' detailed report:

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis

Concert Pharmaceuticals Initiates Phase 1 Trial Evaluating Deuterated Ivacaftor For Cystic Fibrosis

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that is has initiated its Phase 1 clinical program for deuterium-modified ivacaftor, a novel, potentially disease-modifying treatment for cystic fibrosis.

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals Reports Year End 2014 Financial Results

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2014 and provided an update on its product pipeline and corporate activities.

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals To Present At Three Upcoming Investor Conferences

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The 35 th Annual Cowen and Company Healthcare...

Concert Pharmaceuticals To Report Full Year 2014 Results On February 27, 2015

Concert Pharmaceuticals To Report Full Year 2014 Results On February 27, 2015

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the year ended December 31, 2014 on Friday, February 27, 2015 before the US financial markets open.

Concert Pharmaceuticals Announces Appointment Of James V. Cassella As Chief Development Officer

Concert Pharmaceuticals Announces Appointment Of James V. Cassella As Chief Development Officer

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has appointed James V.

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals To Be Added To NASDAQ Biotechnology Index

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NASDAQ: NBI) effective prior to the market open on Monday, December 22, 2014.

Concert Pharmaceuticals Becomes Oversold (CNCE)

Concert Pharmaceuticals Becomes Oversold (CNCE)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals Names Thomas Auchincloss To Board Of Directors And Chair Of The Audit Committee

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that Thomas G.

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals And Concert Pharmaceuticals Provide JZP-386 Program Update

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals Reports Third Quarter 2014 Financial Results And Provides Update On CTP-354 Program

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the third quarter of 2014 and provided an update on its pipeline and CTP-354.

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals To Present At Stifel 2014 Healthcare Conference On November 18, 2014

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Stifel 2014 Healthcare Conference, November 18, 2014 at 1:50 p.

TheStreet Quant Rating: D (Sell)